Meeting
2024 ASCO Annual Meeting
Efficacy of intrathecal delivery of peptide-pulsed type 1 conventional dendritic cell vaccine for the treatment of breast cancer-associated leptomeningeal disease in preclinical models.
Authors
Vincent Law
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Vincent Law , Colin Snyder , Zhihua Chen , Pawel Kalinski , Brian J. Czerniecki , Peter A. J. Forsyth
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Brain Metastases
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 2030)
DOI
10.1200/JCO.2024.42.16_suppl.2030
Abstract #
2030
Poster Bd #
329
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Safety and preliminary efficacy of intrathecal (IT) and intravenous (IV) nivolumab (N) for patients (pts) with leptomeningeal disease (LMD).
First Author: Isabella Claudia Glitza
Poster
2021 ASCO Annual Meeting
Trial in progress: Phase I/II study of radiation therapy followed by intrathecal trastuzumab/pertuzumab in the management of HER2+ breast leptomeningeal disease.
First Author: Kamran A. Ahmed
Poster
2024 ASCO Annual Meeting
A single center retrospective cohort study of patients with metastatic breast cancer and leptomeningeal disease: Updated survival data and subgroup analyses by breast cancer subtype.
First Author: Samantha Catherine Fisch
Poster
2023 ASCO Annual Meeting
Efficacy from the ongoing phase I trial Study 1100 with NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with locoregionally recurrent or metastatic HNSCC.
First Author: Colette Shen